Study guide

5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

Key Takeaways Explain This Topic AI

Standard 7.1 requires the cancer committee to monitor the program's performance on CoC-selected quality measures against the expected Estimated Performance Rate (EPR) and to implement an action plan for any measure below it.

Standard 7.2 requires a physician to perform an annual retrospective, medical-record-based analysis of whether diagnostic evaluation and first-course treatment were concordant with evidence-based national guidelines.

A 7.2 study reviews all cases of one site (or stage within a site) up to 100 cases, or an identified concern within a site or stage; case discussions at conferences do not satisfy it.

Standard 7.3 requires at least one QI initiative per year with a numeric problem statement, a recognized performance improvement tool (such as Lean, DMAIC, or PDCA/PDSA), and at least two status reports to the committee each year.

QI initiatives last about one year and may be extended to a second year, but a new initiative must still start at the beginning of each calendar year.

Last updated: September 2026

Quality improvement principles

Quality improvement (QI) is the systematic use of data to improve care processes and outcomes. The exam's "quality improvement principles" topic tests ideas that appear in every QI method:

Start from a known problem measured with data. A CoC QI initiative must address an already identified problem. It cannot be a study "to see whether a problem exists."

Measure a baseline and set a numeric goal , for example "raise X from 71% to 85% within 12 months."

Find the root cause before you intervene. Tools include cause-and-effect (fishbone or Ishikawa) diagrams, the 5 Whys , process flow maps and Pareto charts.

Test changes in cycles and keep measuring , using run charts or control charts to see whether the change worked and whether it lasts.

Benchmark against peer, state and national performance, such as NCDB quality measure reports.

Common performance improvement models

Model Steps Typical use

PDSA / PDCA Plan, Do, Study (or Check), Act, repeated in small rapid cycles Testing a process change on a small scale before spreading it

Six Sigma DMAIC Define, Measure, Analyze, Improve, Control Reducing variation and defects in a measurable process

Lean Map the value stream and remove waste (waiting, rework, unnecessary steps) Speeding up referral or treatment pathways

Root cause analysis Identify contributing causes of a specific problem or event Understanding why a care gap occurred

The CoC glossary defines PDCA and PDSA as QI methods, and Standard 7.3 names Lean, DMAIC and PDCA/PDSA as examples of the recognized, standardized tools a QI initiative must use.

Standard 7.1: Quality Measures

The CoC selects quality measures each year and publishes the specifications, evaluation years and performance thresholds on the NCDB website. Performance rates come from the NCDB reporting tools.

The cancer committee monitors the program's performance against the expected Estimated Performance Rate (EPR) for each selected measure and documents the monitoring in the minutes each year.

For any measure below the expected EPR, the program develops and implements an action plan that investigates the causes and works to remove barriers.

A program with no eligible cases for a measure is exempt from that measure.

Accurate registry data come first. A measure can look "failed" because the registry is missing treatment given at another facility, such as radiation or hormone therapy. Following up on treatment given elsewhere before concluding that care was not given is one of the most valuable things a registrar does for quality measures.

Standard 7.2: Monitoring Concordance with Evidence-Based Guidelines

Each calendar year, a physician performs an in-depth analysis of individual patients' care. The study must include:

A study population of either all cases from one site (or one stage within a site) up to a maximum of 100 cases , or an identified need or concern within a specific site or stage.

A medical record review of each patient to decide whether the pre-treatment diagnostic evaluation (pathology, imaging, laboratory tests and recommended consultations) followed evidence-based national guidelines.

A review of each patient's first course of treatment to decide whether it was appropriate for the stage or prognostic indicators and concordant with the guidelines.

A reporting format that supports analysis and improvement.

A presentation of the results to the cancer committee in the same calendar year, documented in the minutes with any recommendations.

Two rules are often tested. Case discussions at cancer conferences do not satisfy Standard 7.2, and patient data reviewed for the Standard 6.1 registry quality control plan cannot be reused as the 7.2 study. Problems a 7.2 study uncovers are a good source for a 7.3 QI initiative.

Standard 7.3: Quality Improvement Initiative

Under the guidance of the Cancer Liaison Physician , the Quality Improvement Coordinator and the cancer committee, the program completes at least one cancer-specific QI initiative each year.

Step Requirement

1. Review data to find the problem Sources, in order of preference: an NCDB quality measure problem; a 7.2 study finding; the annual review of other standards (palliative care, genetics, operative standards); NAPRC or NAPBC initiatives; NCDB or CQIP data; cultural competency, shared decision-making or health equity data; any other cancer-specific quality problem the committee identifies

2. Write the problem statement Name a specific, already-identified problem, the numeric baseline and goal metrics, and the expected timeline

3. Choose a methodology and a team The QI Coordinator and the CLP identify the content experts needed (for example, a breast surgeon and a radiation oncologist for a radiation-after-lumpectomy measure) and use a recognized tool such as Lean, DMAIC or PDCA/PDSA to analyze causes and design an intervention

4. Implement and monitor Put the intervention in place, and change it if monitoring shows it is not working

5. Present a summary The data reviewed, the problem statement, team members, the tool used, the intervention and any adjustments, and the results (compared with national data where possible), documented in the minutes

Reporting and timing:

The CLP or QI Coordinator gives status updates at least twice each calendar year . The final summary may count as one of them.

An initiative should last about one year and may be extended to a second year . The intent to extend must be documented before or during the last meeting of the first year, and a new initiative must start each calendar year anyway.

Programs also accredited by the NAPBC and/or NAPRC may count one completed breast-specific and/or rectal-specific QI initiative toward Standard 7.3 during each accreditation cycle.

The registry's role

QI activity Registry contribution

Finding the problem Pull NCDB quality measure performance, 7.2 results and registry reports, and check that apparent gaps are not missing data

  • Baseline Define the cohort precisely (site, stage, diagnosis years, analytic cases) and calculate the rate
  • Monitoring Produce periodic run charts from registry data during the intervention
  • Reporting Prepare the tables and figures for status updates and the final summary
  • Worked example

A program's performance on a colon measure (at least 12 regional lymph nodes examined after resection) is 78%, below the expected EPR. The registry first confirms the node counts against the pathology reports and finds no abstracting errors. The problem statement reads: "12-node examination rate is 78% (baseline 2025); goal 90% by December 2026." A PDSA team of surgeons, pathologists and pathology assistants finds that grossing protocols vary between shifts. The team standardizes grossing with a fat-clearing step for low counts, and the registry tracks the monthly rate. The CLP reports status in the second and fourth quarters, and the final summary compares the results with national data.

Loading diagram... CoC Standard 7.3 QI initiative cycle